Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Meeting to be held on June 4, 2024 First FDA Advisory Committee meeting for potential new PTSD treatment in 25 years SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Lykos Therapeutics (formerly MAPS...
Allison Rosenthal appointed Chief Commercial Officer to lead the potential commercial launch of MDMA-assisted therapy if approved by the FDA Coy Stout joins as Vice President of Market Access SAN...
Study completion marks an important next step in the Company's Europe program SAN JOSE, Calif., April 24, 2024 /PRNewswire/ -- Lykos Therapeutics (formerly MAPS Public Benefit Corporation)...
PDUFA date is August 9, 2024 If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy SAN JOSE, Calif., Feb. 9, 2024 /PRNewswire/ -- Lykos Therapeutics (formerly...
Participants with severe PTSD who received MDMA-assisted therapy demonstrated significant improvements in self-experience Improvements in self-compassion associated with MDMA-assisted therapy were...